These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19475773)

  • 1. Prevention of diabetes in hypertensive patients: results and implications from the VALUE trial.
    Zhou MS; Schulman IH
    Vasc Health Risk Manag; 2009; 5(1):361-8. PubMed ID: 19475773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-diabetic effect of blockade of the renin-angiotensin system.
    Ando K; Fujita T
    Diabetes Obes Metab; 2006 Jul; 8(4):396-403. PubMed ID: 16776746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes.
    Jandeleit-Dahm KA; Tikellis C; Reid CM; Johnston CI; Cooper ME
    J Hypertens; 2005 Mar; 23(3):463-73. PubMed ID: 15716683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus.
    Lardizabal JA; Deedwania PC
    Curr Cardiol Rep; 2010 Nov; 12(6):464-71. PubMed ID: 20809236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does interference with the renin-angiotensin system protect against diabetes? Evidence and mechanisms.
    van der Zijl NJ; Moors CC; Goossens GH; Blaak EE; Diamant M
    Diabetes Obes Metab; 2012 Jul; 14(7):586-95. PubMed ID: 22226145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].
    Boucek P
    Vnitr Lek; 2006 Sep; 52(9):791-6. PubMed ID: 17091602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease.
    Fonseca VA
    J Clin Hypertens (Greenwich); 2006 Oct; 8(10):713-20; quiz 721-2. PubMed ID: 17028485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on Hypertension Management: treatment of hypertension in patients with type 2 diabetes mellitus.
    Nilsson PM; Cifkova R; Kjeldsen SE
    J Hypertens; 2006 Jan; 24(1):208-10. PubMed ID: 16331123
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes.
    Macfarlane DP; Paterson KR; Fisher M
    Diabetes Obes Metab; 2008 Jul; 10(7):533-44. PubMed ID: 18248492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic and clinical aspects of renin-angiotensin-aldosterone system blockade in the prevention of diabetes mellitus and cardiovascular disease.
    Hershon KS
    Endocr Pract; 2011; 17(3):430-40. PubMed ID: 21454245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting the renin-angiotensin system: why and in which patients.
    Berra K; Miller NH
    J Am Acad Nurse Pract; 2009 Jan; 21(1):66-75. PubMed ID: 19125897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-angiotensin-system blockade in the prevention of diabetes.
    Ostergren J
    Diabetes Res Clin Pract; 2007 May; 76 Suppl 1():S13-21. PubMed ID: 17320999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can two be better than one? Dual RAS blockade in patients with type 2 diabetes and overt nephropathy in the age of ONTARGET and ALTITUDE.
    Lovshin JA; Cherney DZ
    Hypertens Res; 2014 Jan; 37(1):4-6. PubMed ID: 24026039
    [No Abstract]   [Full Text] [Related]  

  • 18. First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus.
    Wang G; Chen Y; Li L; Tang W; Wright JM
    J Hum Hypertens; 2018 Jul; 32(7):494-506. PubMed ID: 29713053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
    Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
    Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers.
    Verdecchia P; Gentile G; Angeli F; Reboldi G
    Ther Adv Cardiovasc Dis; 2012 Apr; 6(2):81-91. PubMed ID: 22528743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.